Literature DB >> 18835039

Posterior reversible encephalopathy syndrome: a case of unusual diffusion-weighted MR images.

A Benziada-Boudour1, E Schmitt, S Kremer, S Foscolo, A-S Rivière, M Tisserand, A Boudour, S Bracard.   

Abstract

Posterior reversible encephalopathy (PRES) represents an uncommon entity related to multiple pathologies, the most common of which is hypertensive crisis. PRES is classically characterized as symmetrical parieto-occipital edema, but may affect other areas of the brain. Diffusion-weighted magnetic resonance imaging (DWI) is important for differentiating between vasogenic and cytotoxic edema. We present here the case of a 43-year-old woman, known to suffer from arterial hypertension and severe renal failure, who developed PRES with restricted apparent diffusion coefficients (ADC) in various cerebral areas, suggesting irreversible tissue damage. Nevertheless, follow-up cranial MRI revealed complete remission, indicating that restricted diffusion does not always lead to cell death in this pathology. The underlying pathophysiological mechanism is not well understood. Such reversibility of diffusion anomalies has already been reported with transient ischemia, vasospasm after subarachnoid hemorrhage and epilepsy but, to our knowledge, never before in PRES.

Entities:  

Mesh:

Year:  2008        PMID: 18835039     DOI: 10.1016/j.neurad.2008.08.003

Source DB:  PubMed          Journal:  J Neuroradiol        ISSN: 0150-9861            Impact factor:   3.447


  13 in total

1.  Reversible cytotoxic brain edema and facial weakness in uremic encephalopathy.

Authors:  Harald Prüss; Eberhard Siebert; Florian Masuhr
Journal:  J Neurol       Date:  2009-04-12       Impact factor: 4.849

2.  Hypertension-induced posterior reversible encephalopathy syndrome as the presentation of progressive bilateral renal artery stenosis.

Authors:  Aurelio Negro; Gianni De Berti; Massimo Maggi; Rosaria Santi; Chiara Grasselli; Ermanno Rossi
Journal:  J Cardiol Cases       Date:  2011-10-04

Review 3.  [Posterior reversible encephalopathy syndrome].

Authors:  D Staykov; S Schwab
Journal:  Nervenarzt       Date:  2012-08       Impact factor: 1.214

Review 4.  Atypical presentation of posterior reversible encephalopathy syndrome: Clinical and radiological characteristics in eclamptic patients.

Authors:  Aleksandra Aracki-Trenkić; Dragan Stojanov; Milan Trenkić; Zoran Radovanović; Jelena Ignjatović; Saša Ristić; Marija Trenkić-Bozinović
Journal:  Bosn J Basic Med Sci       Date:  2016-06-20       Impact factor: 3.363

5.  5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer.

Authors:  Gyanendra Acharya; Maria T Cruz Carreras; Terry Wynne Rice
Journal:  BMJ Case Rep       Date:  2017-11-21

Review 6.  Posterior reversible encephalopathy syndrome in children with kidney diseases.

Authors:  Kenji Ishikura; Yuko Hamasaki; Tomoyuki Sakai; Hiroshi Hataya; Robert H Mak; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2011-05-11       Impact factor: 3.714

7.  Children with posterior reversible encephalopathy syndrome associated with atypical diffusion-weighted imaging and apparent diffusion coefficient.

Authors:  Kenji Ishikura; Yuko Hamasaki; Tomoyuki Sakai; Hiroshi Hataya; Tomohide Goto; Sahoko Miyama; Tatsuo Kono; Masataka Honda
Journal:  Clin Exp Nephrol       Date:  2010-12-10       Impact factor: 2.801

8.  Posterior Reversible Encephalopathy Syndrome: The Spectrum of MR Imaging Patterns.

Authors:  O Kastrup; M Schlamann; C Moenninghoff; M Forsting; S Goericke
Journal:  Clin Neuroradiol       Date:  2014-02-20       Impact factor: 3.649

Review 9.  The many faces of posterior reversible encephalopathy syndrome.

Authors:  C J Stevens; M K S Heran
Journal:  Br J Radiol       Date:  2012-12       Impact factor: 3.039

10.  Posterior Reversible Encephalopathy Syndrome (PRES): Restricted Diffusion does not Necessarily Mean Irreversibility.

Authors:  Alaa Wagih; Laila Mohsen; Moustafa M Rayan; Mo'men M Hasan; Ashraf H Al-Sherif
Journal:  Pol J Radiol       Date:  2015-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.